Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib + Afatinib in advanced esophageal squamous cell carcinoma
NCT05865132Phase 2Recruiting
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib and afatinib in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Objective Response Rate at 3 years. Started Apr 2023; status: recruiting.
02
Drugs
palbociclibafatinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05865132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05865132.